 Home > Active Ingredient News > Antitumor Therapy > Sirona Pharmaceuticals achieved 100% complete remission in Phase II clinical trials of its skin cancer siRNA drug, siRNA technology may usher in a golden decade?

Sirona Pharmaceuticals achieved 100% complete remission in Phase II clinical trials of its skin cancer siRNA drug, siRNA technology may usher in a golden decade?

 Last Update: 2022-09-08
 Source: Internet
 Author: User

Tags

exchange number

high step stool

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Aug.

In addition to achieving a 100% CR, data from the 5 treated subjects in the cohort showed improved or stable cosmetic outcomes, no apparent skin reactions, and an excellent safety profile (no adverse events)

The Phase II open-label, dose-escalation study will also expand the number of participating cohorts to continue evaluating the safety, tolerability and efficacy of various doses of STP705 administered locally in BCC patients

siRNA drugs may usher in a golden decade

➤Short R&D cycle and wide drug targets: Small molecule and antibody drugs need to recognize the complex spatial conformation of certain proteins, requiring large-scale screening, and even many targets cannot be developed because they cannot be exposed or their conformations are too complex

➤The treatment effect lasts for a long time: Generally speaking, the half-life of small molecule drugs in the body is calculated in hours, and the half-life of antibody drugs is calculated in days, while siRNA drugs can be reused many times in the body, and the half-life is calculated in months, so the frequency of dosing can be reduced.

But again, everything has two sides

Therefore, chemical modification and delivery systems are the key to siRNA drug development, as well as the technical barriers to siRNA drug development
.

Summarize

With Alnylam, Arrowhead and other companies making major breakthroughs in siRNA technology and accelerating the commercialization of siRNA products, the siRNA track has become a hot research and development area
.

Driven by huge patient demand and capital, siRNA technology is expected to usher in a golden decade
.

For companies that deploy siRNA, the technology platform and pipeline progress are the core competitiveness.
How to improve the efficacy and safety through drug design, how to break through the bottleneck of chemical modification and delivery systems, and establish their own moat will be a major test for the company.
It is also an opportunity for business
.

References:

1 Official website of each company

——List of recent popular activities——

▼August 31, new technology for membrane protein target development

▼September 8, iPSC-derived cell drug development strategy

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.